TG103
A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
CSPC Baike (Shandong) Biopharmaceutical Co · Phase 2 · Completed · Enrollment 314
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| TG103 7.5 mg | n/r | n/r | n/r | n/r |
| Placebo 7.5 mg | n/r | n/r | n/r | n/r |
| TG103 15 mg | n/r | n/r | n/r | n/r |
| Placebo 15 mg | n/r | n/r | n/r | n/r |
| TG103 22.5 mg | n/r | n/r | n/r | n/r |
| Placebo 22.5 mg | n/r | n/r | n/r | n/r |
Not shown
- TG103 7.5 mg: endpoint not reported
- Placebo 7.5 mg: endpoint not reported
- TG103 15 mg: endpoint not reported
- Placebo 15 mg: endpoint not reported
- TG103 22.5 mg: endpoint not reported
- Placebo 22.5 mg: endpoint not reported